Adaptive Biotechnologies (NASDAQ:ADPT) Chief People Officer Lo Francis completed a sale of 38,074 common shares on March 5, 2026, at a per-share price of $15.09, producing total proceeds of $574,536. According to the transaction details, the disposition was executed to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
Following the sale, Francis retains direct ownership of 321,967 shares of Adaptive Biotechnologies Corp and holds an additional 2,500 shares indirectly through a spouse, identified as You Jin Lee. At the time the transaction was reported, the company’s shares were trading at $14.95, reflecting a decline of roughly 7% over the prior week while remaining up about 124% over the past 12 months.
In a separate disclosure of corporate performance, Adeptus Biotechnologies Corp reported fourth-quarter 2025 results that outpaced analyst expectations. The company recorded adjusted earnings per share of -$0.09 versus a consensus estimate of -$0.18. Revenue for the quarter came in at $71.7 million, exceeding the expected $59.33 million and representing a beat of approximately 20.85% versus projections.
Analyst reactions to the quarterly data included upward revisions to price targets. TD Cowen raised its price target on Adeptus Biotechnologies to $21 while maintaining its prior rating. BTIG increased its price target to $22, citing particularly strong expansion in the company’s core Minimal Residual Disease, or MRD, business. The MRD segment grew 54% year over year in the fourth quarter and contributed to a 46% revenue increase for the full year, according to the disclosed figures.
These developments followed the insider sale by the company’s chief people officer and offer two distinct data points for investors: a routine executive liquidity event tied to RSU tax obligations, and operational momentum reflected in quarterly results and analyst target adjustments. The transaction and the earnings announcement were reported as separate items in public filings and company disclosures.
There is no indication in the filings that the insider sale was related to any other corporate development beyond the stated tax-withholding purpose. Likewise, the company’s quarterly results and the analyst commentary were presented as performance outcomes and subsequent reassessments of price targets by the named firms.
Summary of key facts:
- Insider sale: 38,074 shares sold at $15.09 on March 5, 2026, totaling $574,536.
- Post-transaction holdings: 321,967 shares directly owned by Lo Francis; 2,500 shares indirectly owned through spouse You Jin Lee.
- Reason for sale: to cover tax withholding obligations tied to RSU vesting.
- Company performance: Adeptus Biotechnologies reported Q4 2025 EPS of -$0.09 and revenue of $71.7 million, beating estimates.
- Analyst moves: TD Cowen raised its price target to $21; BTIG increased its target to $22, noting MRD growth of 54% y/y in Q4 and 46% revenue growth for the full year.